粘菌素
舒巴坦钠
鲍曼不动杆菌
亚胺培南
医学
抗生素
微生物学
碳青霉烯
钙不动杆菌
不动杆菌
内科学
抗生素耐药性
生物
细菌
铜绿假单胞菌
遗传学
作者
Alita A. Miller,Samir H. Moussa,Sarah M. McLeod
摘要
s complex (ABC) causes severe, difficult-to-treat infections that are frequently antibiotic resistant. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat ABC infections, including those caused by multidrug-resistant strains. In a global, pathogen-specific, randomized, controlled phase 3 trial (ATTACK), the efficacy and safety of SUL-DUR were compared to colistin, both dosed with imipenem-cilastatin as background therapy, in patients with serious infections caused by carbapenem-resistant ABC. Results from ATTACK showed that SUL-DUR met the criteria for non-inferiority to colistin for the primary efficacy endpoint of 28-day all-cause mortality with improved clinical and microbiological outcomes compared to colistin. This report describes the characterization of the baseline ABC isolates from patients enrolled in ATTACK, including an analysis of the correlation of microbiological outcomes with SUL-DUR MIC values and the molecular drivers of SUL-DUR resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI